Nascent Stem Cell Company Raises Ethical and Medical Issues
By Bernadette Tansey,
San Francisco Chronicle
| 10. 29. 2007
A San Carlos startup is offering to create "personalized" stem cells from the spare embryos of fertility clinic clients on the chance that the cells, frozen and stored away, may some day help a family member benefit from medical breakthroughs.
The novel business plan of StemLifeLine Inc. - which started promoting its service to fertility patients earlier this year as "insurance for the future" - set off a flash fire of protest from stem cell research opponents and supporters alike.
The outcry from anti-abortion groups wasn't surprising. StemLifeLine derives stem cells from very early stage human embryos, which are destroyed in the process. Opponents of the research see this as the moral equivalent of killing a child. This belief is the basis of the Bush administration's limits on federal funding of embryonic stem cell research.
But some of the most fervent denunciations of StemLifeLine came from vigorous supporters of embryonic stem cell research. Two Stanford University critics aired their complaints in newspaper editorial pages. A prominent Stanford ethicist challenged UC San Francisco scientists who are advisers of the company to...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...